NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

$10.00
-0.10 (-0.99%)
(As of 05/3/2024 08:53 PM ET)
Today's Range
$10.00
$10.10
50-Day Range
$8.61
$15.71
52-Week Range
$4.50
$16.19
Volume
700 shs
Average Volume
16,347 shs
Market Capitalization
$32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Surrozen MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($9.19) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

671st out of 904 stocks

Biological Products, Except Diagnostic Industry

108th out of 153 stocks

SRZN stock logo

About Surrozen Stock (NASDAQ:SRZN)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

SRZN Stock Price History

SRZN Stock News Headlines

Dems have chosen Biden replacement?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Dems have chosen Biden replacement?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Surrozen Provides Corporate Update on Clinical Programs
3 Biotech Stocks to Watch in November
Surrozen Provides Third Quarter 2023 Financial Results
Surrozen Inc Ordinary Shares SRZN
Surrozen GAAP EPS of -$0.31
See More Headlines
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
5/05/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRZN
Fax
N/A
Employees
42
Year Founded
N/A

Profitability

Net Income
$-43,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.50 million
Book Value
$18.39 per share

Miscellaneous

Free Float
2,079,000
Market Cap
$32 million
Optionable
Not Optionable
Beta
0.88
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Craig C. Parker M.B.A. (Age 62)
    CEO, President & Director
    Comp: $825.32k
  • Mr. Charles Williams (Age 44)
    CFO, COO & Corporate Secretary
    Comp: $611.03k
  • Dr. Li Yang Ph.D. (Age 55)
    Executive Vice President of Research
    Comp: $535.46k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Roeland Nusse Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Calvin Kuo M.D.
    Ph.D., Co-Founder & Member of Scientific Advisor
  • Esther Jhun
    Controller

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed in 2024?

Surrozen's stock was trading at $9.40 on January 1st, 2024. Since then, SRZN stock has increased by 6.4% and is now trading at $10.00.
View the best growth stocks for 2024 here
.

Are investors shorting Surrozen?

Surrozen saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 36,200 shares, an increase of 358.2% from the March 31st total of 7,900 shares. Based on an average daily volume of 16,700 shares, the short-interest ratio is presently 2.2 days. Currently, 1.9% of the shares of the company are short sold.
View Surrozen's Short Interest
.

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SRZN earnings forecast
.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) posted its earnings results on Monday, November, 15th. The company reported ($7.65) earnings per share for the quarter, missing the consensus estimate of ($5.85) by $1.80.

When did Surrozen's stock split?

Surrozen's stock reverse split on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRZN) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners